Pioneering Specialists In Precision Epigenetics And Nuclease Biology

At Epicelya Therapeutics, we are dedicated to shaping the future of genetic healthcare. By exploring new frontiers in biology and harnessing cutting-edge mRNA technologies, we believe that “Impossible is not a fact – Impossible is temporary.” Our mission is to master most challenging diseases where traditional therapies have failed or lack appropriate targets.

OUR CORE

Rooted in
cutting-edge science

Build on a robust history of research and expertise in epigenetics, cell biology, drug development and tissue engineering.

Fostering collaboration

Cultivate a collaborative environment, engaging both our internal team and external partners, and work alongside the brightest minds in the industry.

Making a positive impact

Our mission is to create meaningful change through compassionate actions, innovative solutions, and ethical practices that benefit society as a whole.

OUR STORY

Our founding team united to harness revolutionizing technologies that address seemingly impossible challenges. With our combined expertise, we are committed to push the boundaries of what is possible and turn groundbreaking biological discoveries into life-changing clinical solutions.

What defines us is not our individual identities, but our collective impact. Together, we focus on what we can achieve and how we contribute to our community and beyond.

MEET OUR TEAM

LEADERSHIP

Dr. Jürg Stebler, MBA

Chief Executive Officer,
Co-Founder

Dr. Sara Laudato

Chief Scientific Officer,
Co-Founder

Dr. Emily McLaren

Head of Technology
Development

Kaspar Kunz

Chief Financial Officer
(Part-time)

SCIENTIFIC AND CLINICAL ADVISORY BOARD

Our distinguished scientific advisory board provides invaluable expertise and guidance

Dr. Claire Barton, MD PhD

Professor Dr. Christoph Plass

PD Dr. Marco Wachtel

Dr. Jürg Stebler, MBA

Chief Executive Officer, Co-Founder

Jürg is the co-founder and Chief Executive Officer of Epicelya, bringing with him over two decades of leadership experience in the pharma-biotech industry across several key areas. Before co-founding Epicelya, Jürg served as CEO of CureOmics, where he led the innovation of the next-generation products in the field of regenerative medicine and aging. Prior to that, he was the Head of Pharma Development at DCS Pharma (acquired by IMCD), where he was responsible for global partnerships with pharma companies, as well as regulatory affairs, and quality assurance. Earlier in his career, he served as Head of R&D at Xeltis, pioneering the development of cardiovascular tissue-engineered therapies in Europe, and played a crucial role in its financing and M&A activities, leading to the successful acquisition of QTIS/e. Jürg began his career at Novartis, followed by multiple roles at Kuros Biosurgery in non-clinical and clinical research and operations across oncology, cardiovascular diseases, and dermatology.

Jürg holds a PhD in molecular biology from the Max Planck Research School and the University of Göttingen, with a research focus on stem cell integrity, motility, and cancer development. He also earned an MBA from IE Business School in Madrid and a B.Sc. in Chemistry from the Zurich University of Applied Sciences.

Dr. Sara Laudato

Chief Scientific Officer, Co-Founder

Sara is co-founder and Chief Scientific Officer at Epicelya. She brings extensive expertise in oncology, cell biology, and translational development, alongside over a decade of experience in academia and industry. Prior to Epicelya, Sara was with TOLREMO Therapeutics, a Swiss biotech company, where she co-developed an epigenetic small molecule drug now in clinical trials for the treatment of solid tumors. Her contributions were instrumental in understanding the mode-of-action of the lead molecule, guiding its preclinical development and translational strategy up to IND filing as the drug transitioned into the clinic.

Sara completed her postdoctoral training at MD Anderson Cancer Center in Houston, focusing on drug resistance mechanisms to targeted therapies in prostate cancer and on identifying metastatic drivers through CRISPR/Cas9 in vivo genetic screens. She holds a PhD in biomedical sciences from the German Cancer Research Center (DKFZ) and Ruprecht Karls Universität Heidelberg, where she investigated the role of miRNAs in regulating tissue invasion and intestinal cancer.

Dr. Emily McLaren

Head of Technology Development

Emily is the Head of Technology Development at Epicelya. She has over a decade of experience in precision epigenetic editing and nuclease technology. Her expertise is demonstrated through numerous publications and significant research contributions in the field. Before joining Epicelya, Emily was Project Leader at a stealth biotech start-up, where she led the design and execution of genome engineering approaches.

Emily completed her postdoctoral work at the Barts Cancer Institute, UK, where she developed precision epigenetic editing tools to explore the causative role of epigenetics in oncology. Later, as a recipient of the prestigious Kay Kendall Leukemia Fund, she employed precision epigenetic editing to functionally explore leukaemia initiation and progression. Emily earned her PhD from the University of Bristol where she investigated the mechanisms by which epigenetic changes can drive adaptive memory in rodent models.

Kaspar Kunz

Chief Financial Officer (Part-time)

Kaspar is part-time Chief Financial Officer for Epicelya and founding partner at Hoffmann & Partner. In his role, he brings a wealth of pharma-biotech specific financial expertise and strategic insight on budgeting, forecasting, valuation, M&A, accounting, and due diligence.

Before founding Hoffmann & Partner, Kaspar worked for a Big-4 Service provider in Switzerland, Australia, and New Zealand for over ten years. During this time, he led numerous audits and IFRS mandates for companies of various sizes across these regions. His extensive international experience is particularly valued for complex, cross-border mandates.

Kaspar Kunz graduated as a business economist from the University of Applied Sciences of Basel and is also a Swiss certified accountant.

Dr. Claire Barton, MD PhD

Claire is a medical oncologist and pharmaceutical physician specializing in the clinical development of products for oncology indications. Her experience spans both biotech and major pharmaceutical companies, including Glaxo-Wellcome, Eli-Lilly, Roche, and many smaller companies, including T3 Pharma AG (acquired by Boehringer Ingelheim), for which she was CMO. In addition to her industry roles, Claire works with academic and charitable organizations, including the PTEN Research Foundation and Wellcome Trust.

Claire has extensive experience of clinical development, ranging from strategic planning and first-in human studies to regulatory approvals. She has worked on a variety of products including genetically-modified organisms, monoclonal antibodies and derivatives, cellular therapies, targeted agents, hormonal therapies, cytotoxics and pro-drugs. She is also experienced at evaluating in-licensing opportunities, and is chairman of the Oncology Expert Group for the UK’s Faculty of Pharmaceutical Medicine.

Professor Dr. Christoph Plass

Christoph is the head of the Division of Cancer Epigenomics at the German Cancer Research Center (DKFZ) in Heidelberg. His research focuses on the epigenetic mechanisms driving cancer, with pioneering discoveries in DNA methylation and its role in cancer, particularly in leukemias and solid tumors of the lung, head and neck, and prostate.

Before joining DKFZ, Christoph spent over 15 years in the U.S., holding prominent academic and research positions at the Roswell Park Cancer Institute and Ohio State University, where he served as a Professor in the Department of Human Cancer Genetics. He earned his PhD in Molecular Genetics from the Medical University of Lübeck, Germany.

Christoph’s contributions to science have been widely recognized. He has authored over 400 research articles in prestigious journals, serves as Editor-in-Chief of the International Journal of Cancer, and is an active member of several renowned societies, including the Mammalian Genome Society, the Society for Neuro-Oncology, the American Association for Cancer Research, and the American Society for Human Genetics.

PD Dr. Marco Wachtel

Marco is a leading expert in rare pediatric tumors and a cancer researcher at the University Children’s Hospital in Zurich. He has a long-standing interest in the biology of pediatric sarcomas, with his research focused on understanding these tumors at the molecular and cellular levels and developing more effective therapies. Among his translational efforts, Marco developed a high-throughput drug profiling platform using a living biobank of primary sarcoma xenografts.

Marco habilitated at the medical faculty of the University of Zurich and he earned his PhD from the Swiss Federal Institute of Technology (ETH) Zurich.